The increasing uptake of Carvykti, driven by its attractive clinical profile and favorable outpatient dosing, has led to significant sales growth. The company’s efforts to expand manufacturing ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Net Trade Sales of CARVYKTI: Approximately $286 million, an 87.6% increase year-over-year and a 53.2% increase ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Turning to our highlights. In the third quarter, we are pleased that CARVYKTI cells continued their strong momentum, ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

The study – which tested Carvykti in patients with one to three lines of prior therapy – gives J&J an opportunity to leapfrog Bristol-Myers Squibb and 2Seventy bio's rival BCMA CAR-T therapy ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Their CARVYKTI therapy, which targets BCMA, has been approved by both the FDA and European Commission, and is expanding its reach globally. This development highlights potential growth ...